Analysis
Boston Scientific faces a significant cost headwind from U.S. tariffs introduced in April 2025, which include "reciprocal" tariffs and a 10% blanket tariff on imported components. The company initially forecasted a $200M gross impact for FY2025, primarily driven by back-and-forth duties between the U.S. and China. While the initial estimate was high, the realized net impact for 2025 was approximately $100M, as the tariffs were subject to a 90-day pause and only hit the P&L in the second half of the year following the standard turnover of finished goods inventory.
Management has implemented a multi-pronged strategy to mitigate the tariff-related margin pressure. This includes raising organic revenue guidance and executing targeted reductions in discretionary spending, specifically in areas such as travel and internal meetings. By the third quarter of 2025, the company successfully offset much of the headwind through strong performance in its cardiovascular segment and favorable product mix, which allowed gross margins to remain slightly above prior-year levels despite the tariff costs.
For 2026, Boston Scientific anticipates an additional headwind from the "annualization" of these tariffs, as the 2025 results only reflected a partial year of impact. The company expects the annualized cost to reach approximately $200M. The CFO noted that while favorable product mix should continue to support margins, this will likely be offset by the combination of full-year tariff costs and ongoing investments in the global supply chain. The company remains committed to its long-term operating margin expansion goals and continues to leverage its diversified manufacturing footprint, including recent site investments in Georgia and Minnesota, to optimize its supply chain.
Data
($M)
| Tariff Impact Detail | FY2025A | FY2026E |
|---|---|---|
| Estimated Gross Tariff Headwind | $200.0 | $200.0 |
| Realized Net Cost Impact | (100.0) | (200.0) |
| Mitigation Strategy | Expense & Sales | Efficiency & Pricing |
Source: Company filings, Marvin Labs
Financial Impact
- Cost Impact (Historic): $100M
- Cost Impact (Forward-Looking): $200M
Sources
This also includes an approximate $200mn impact from tariffs based on the information that is available today which we expect to offset through sales upside and smart reductions in discretionary spending.
The reciprocal tariff rates that were put in place on April 2 with the 90 day pause would then commence early in Q3. We assume they commence in early Q3 and tariff. It's the 145 U.S., 125 China back and forth that's there now and that's actually the largest component of that $200mn for us.
In 2026, we anticipate full year adjusted gross margin to be roughly in line with full year 2025, as we expect favorable product mix to be largely offset by investments in our global supply chain and the annualization of tariffs.